Cite
HARVARD Citation
Choueiri, T. et al. (2018). Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. Lancet oncology. 19 (4), pp. 451-460. [Online].